Cell Therapeutics, the Seattle-based developer of cancer drugs, said today that the FDA has agreed to review the company’s application to market pixantrone for non-Hodgkin’s lymphoma in the U.S. The company (NASDAQ: [[ticker:CTIC]]) is seeking an expedited six-month review for the drug, which is sometimes granted for treatments with life-saving potential. The FDA will decide on its deadline for reviewing the Cell Therapeutics application by Sept. 4, the company said. The treatment, a form of anthracycline chemotherapy, was designed to be less toxic to the heart than other drugs in its class.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
